Meetings - The ASCO Post

This is Part 3 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video...

prostate cancer

/ Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer

Case 2: High-Risk De Novo Metastatic Hormone-Sensitive Prostate Cancer

This is Part 2 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video...

prostate cancer

/ Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer

Case 1: De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer With PTEN Deficiency

This is Part 1 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this vide...

Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer

Case 3: Recurrent Low-Volume Metastatic Hormone-Sensitive Prostate Cancer

Case 2: High-Risk De Novo Metastatic Hormone-Sensitive Prostate Cancer

Case 1: De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer With PTEN Deficiency

Addition of Glofitamab to R-CHOP or Pola-R-CHP in Younger Patients With High-Risk LBCL

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

PPP2R1A Mutations Linked to Improved Immunotherapy Outcomes in Ovarian Clear Cell Carcinoma

Bevacizumab Plus Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer